source
- Cytokinetics' HCM drug shows positive trial results, potentially doubling market after Bristol Myers' setbackCytokinetics announced that its oral therapy for hypertrophic cardiomyopathy (HCM) achieved positive results in a pivotal trial targeting a different form of the disease. The data suggest the drug…
- Microbiome startup Kanvas Biosciences secures $48 million to advance immunotherapy and malnutrition therapiesKanvas Biosciences announced it has closed a $48 million financing round to fund development of microbiome-based treatments targeting cancer immunotherapy response and severe malnutrition. The cap…